SS-31 (elamipretide) is a mitochondria-targeted peptide that became the base molecule behind FORZINITY, the first FDA-approved mitochondrial peptide therapy, in October 2025. This update covers what that approval does and doesn't change for SS-31 research materials sold in the UK.
What is SS-31?
SS-31 is a synthetic tetrapeptide designed to concentrate specifically in the inner mitochondrial membrane, where it's proposed to interact with cardiolipin, a phospholipid essential to mitochondrial membrane structure and the electron transport chain. It belongs to the Szeto-Schiller (hence "SS") family of mitochondria-targeted peptides developed initially as research tools for studying mitochondrial function, before becoming a serious drug-development candidate in its own right.
The 2025 FORZINITY approval — what actually happened
In October 2025, elamipretide received FDA approval under the brand name FORZINITY for Barth syndrome, a rare genetic mitochondrial disorder, based on open-label data from the TAZPOWER trial programme measuring muscle strength outcomes. This made it the first FDA-approved therapy specifically targeting mitochondrial function via this mechanism — a genuinely significant milestone for the mitochondrial peptide field as a whole, and worth distinguishing from SS-31's separate, larger trial history in other conditions (including primary mitochondrial myopathy, heart failure with preserved ejection fraction, and geographic atrophy), where earlier Phase 2/3 studies did not meet their primary endpoints.
What this means — and doesn't mean — for UK research use
FORZINITY is a licensed pharmaceutical product, approved by the FDA for a specific rare-disease indication in the United States, manufactured and formulated under a pharmaceutical-grade process entirely separate from research-grade SS-31 sold for laboratory use. The approval does not change SS-31's regulatory status in the UK: it remains an unlicensed compound here, with no UK marketing authorisation, and research-grade SS-31 should not be conflated with, or marketed alongside, the approved drug product.
What the wider research shows
Beyond the Barth syndrome approval, the SS-31/elamipretide literature includes:
- Cardiolipin-binding studies establishing the proposed mechanism of mitochondrial membrane stabilisation.
- Cardiac and skeletal muscle models, examining mitochondrial function markers in various injury and disease models.
- The broader Phase 2/3 trial programme in HFpEF and geographic atrophy, both of which failed to meet primary endpoints — an important part of the evidence picture that shouldn't be omitted when discussing the FORZINITY approval.
Research status and open questions
The FORZINITY approval demonstrates that this mechanism can, in a narrow and specific context, translate into a licensed therapy — a meaningful proof point for the mitochondrial-targeting peptide field generally. But the mixed trial history in other indications is a useful reminder that a single successful approval doesn't validate every proposed use of a compound, and researchers studying SS-31 in other contexts are working from a considerably less settled evidence base.
UK regulatory status
Research-grade SS-31 carries no UK marketing authorisation and is supplied strictly for laboratory research use, unrelated to the FORZINITY drug product approved elsewhere.
Sourcing research-grade SS-31 in the UK
Given the increased public attention SS-31 has received since the FORZINITY approval, checking that a UK supplier's SS-31 listing doesn't blur the line with the approved drug product is worth doing before ordering — that distinction should be explicit on the product page. Flex Peptides lists SS-31 with COA data available on request, UK-based dispatch, and clear separation from the FORZINITY drug product in its product description.
Study Design Considerations for SS-31 Research
Researchers studying SS-31/elamipretide should pay close attention to which trial or study population a given finding comes from, given the compound's unusually varied evidence base — spanning a successful rare-disease approval, mixed results in more common cardiac and ophthalmic indications, and a broader preclinical literature on cardiolipin binding. This variance means that citing "SS-31 research" without specifying which strand is being referenced can be misleading, and careful researchers typically specify whether they're discussing the Barth syndrome trial data, the HFpEF/geographic atrophy programmes, or the earlier mechanistic cardiolipin-binding studies, since these represent quite different levels and types of evidence.
For laboratory researchers working with the research-grade compound specifically, it's also worth noting that mitochondrial isolation and functional assay protocols (measuring membrane potential, ATP production, or reactive oxygen species) vary considerably between published SS-31 papers, and methodological details in the original paper's methods section should be checked closely before attempting to replicate a specific finding.
Key takeaways
- SS-31 (elamipretide) is a mitochondria-targeted peptide, proposed to act via cardiolipin binding.
- It became FORZINITY, the first FDA-approved mitochondrial peptide therapy, in October 2025 for Barth syndrome.
- Earlier Phase 2/3 trials in other indications (HFpEF, geographic atrophy) did not meet primary endpoints.
- The approval does not change SS-31's unlicensed regulatory status for research-grade material sold in the UK.
- Suppliers should clearly separate research-grade SS-31 from the approved FORZINITY drug product.
FAQ
Does the FORZINITY approval mean SS-31 is now legal to sell as a treatment in the UK?
No — FORZINITY is a separate, licensed pharmaceutical product approved in the US for a specific indication; research-grade SS-31 remains an unlicensed research chemical in the UK.What is Barth syndrome?
A rare genetic mitochondrial disorder affecting muscle strength and cardiac function, and the specific indication for which FORZINITY was approved.Why did SS-31 succeed in Barth syndrome but not in HFpEF or geographic atrophy trials?
The published literature doesn't offer a single settled explanation — differences in patient population, disease mechanism, dosing, and trial endpoints have all been discussed as possible contributing factors, and this remains a topic of ongoing analysis in the field.Should researchers expect SS-31's mechanism to work the same way across different tissue types?
Not necessarily — mitochondrial density, cardiolipin content and baseline function vary meaningfully between tissue types, which is one reason the compound's clinical trial results have differed across indications.
For laboratory research use only. Not for human or veterinary use. This article does not imply that Flex Peptides' SS-31 product is equivalent to, or a substitute for, the licensed FORZINITY drug product.
